Los Angeles / Hong Kong, June 30, 2010 - Artificial Life, Inc., (OTCPK: ALIF) (http://www.artificial-life.com), a leading provider of award-winning mobile 3G technology and applications, announced today their soon to be launched mobile telemedicine health solution GluCoMo (short for: GluCose Monitor), the first in a series of planned mobile healthcare products.

GluCoMo is a diabetes management solution leveraging Artificial Life's OPUS-M™ platform for end-consumers, healthcare providers and healthcare businesses. GluCoMo is scheduled for commercial availability in July, 2010.

The application is a mobile telemedicine and healthcare solution allowing diabetics, caregivers, doctors, and hospitals to share and communicate through mobile mediums such as smartphones, tablets, netbooks and other mobile internet devices. With the facilitation of mobile data sharing and smart back-end processes, the goals are to promote better personal diabetes management habits, increase peace of mind for friends, families and caregivers, and enable remote and real time monitoring and management of patients by doctors and hospitals for advancement in healthcare services and a reduction in administration costs.

GluCoMo is a customized mobile device front-end client and portal as well as a custom back-end infrastructure supported by Artificial Life's m-commerce solution OPUS-M:

The GluCoMo front-end is comprised of two parts, a mobile client and web portal. The mobile client is able to support most major smartphone platforms allowing users to keep track of relevant information in real time such as blood sugar levels, calorie intake, personal activities, medication intake and more. Visualization of the data gives users quick snapshots of their medical history. Sharing of information is also simplified and promoted through online social communities and forums so that users can quickly share their latest medical status, diabetic activities and medical information with others. For greater flexibility and convenience, a synchronized web portal is also available for users, their friends, family members and caregivers.

The GluCoMo back-end is powered by Artificial Life's OPUS-M technology and allows for friends, families, and caregivers to share critical information and thoughts with each other.

The front-end mobile client of GluCoMo will initially be launched as a limited free mobile app and service. Depending on the needs of the users, additional features and functions for the mobile client can then be purchased inside the mobile app in the coming versions.

GluCoMo will soon also be offered as a white label solution and can be adopted by doctors, health clinics, hospitals and/or healthcare industry businesses. The pricing of the customization, integration and maintenance services are based on monthly rental and usage fees.

"Artificial Life further expands its business app portfolio by launching a first and powerful mobile medical solution for diabetics. Other telemedicine products will follow" said Eberhard Schoneburg, CEO of Artificial Life, Inc.